Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Japan Atherosclerosis Society Country of Publication: Japan NLM ID: 9506298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-3873 (Electronic) Linking ISSN: 13403478 NLM ISO Abbreviation: J Atheroscler Thromb Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tokyo : Japan Atherosclerosis Society
    • Subject Terms:
      Insulin Resistance*; Cholesterol, LDL/*blood ; Lipoprotein(a)/*blood ; Proprotein Convertase 9/*blood ; Triglycerides/*blood; Aged ; Blood Pressure Determination/methods ; Blood Pressure Determination/statistics & numerical data ; Body Mass Index ; Correlation of Data ; Female ; Humans ; Japan/epidemiology ; Male ; Medical History Taking/methods ; Medical History Taking/statistics & numerical data ; Population Surveillance ; Risk Factors
    • Abstract:
      Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been identified as an important regulator of low-density lipoprotein (LDL) receptor processing. Evolocumab and alirocumab are PCSK9 inhibitors; however, little is known about the association between PCSK9 levels and lipid profiles in a general population. Because PCSK9 inhibitors have LDL-C lowering effects, we investigated whether there is a positive correlation between serum PCSK9 levels and LDL-C or lipoprotein(a) [Lp(a)].
      Methods: In Uku town, 674 residents (mean age; 69.2±8.3 years) received health check-ups. The participants underwent a physical examination and blood tests, including PCSK9 and Lp(a). Serum PCSK9 and Lp(a) were measured by ELISA and Latex methods, respectively. HOMA-IR was calculated by fasting plasma glucose×insulin levels/405.
      Results: The mean (range) of PCSK9 and Lp(a) were 211.2 (49-601) ng/mL and 60 (1-107) mg/dL, respectively. Because of a skewed distribution, the log-transformed values were used. With univariate linear regression analysis, PCSK9 levels were associated with Lp(a) (p=0.028), triglycerides (p＜0.001), and HOMA-IR (p＜0.001), but not with LDL-C (p=0.138) levels. Multiple stepwise regression analysis revealed that serum PCSK9 levels were independently associated with triglycerides (p＜0.001), Lp(a) (p=0.033) and HOMA-IR (p=0.041).
      Conclusions: PCSK-9 is independently associated with triglycerides, Lp(a) levels, and HOMA-IR, but not LDL-C, in a relatively large general population sample.
    • References:
      J Endocrinol Invest. 2016 Aug;39(8):875-83. (PMID: 26894681)
      Ann Med. 2016 Aug;48(5):384-91. (PMID: 27222915)
      Hypertens Res. 2006 Dec;29(12):961-7. (PMID: 17378368)
      Clin Investig Arterioscler. 2016 Mar-Apr;28(2):71-8. (PMID: 26743379)
      JAMA. 2016 Aug 16;316(7):743-53. (PMID: 27533159)
      J Clin Invest. 1994 Jun;93(6):2526-34. (PMID: 8200989)
      J Atheroscler Thromb. 2019 Mar 1;26(3):282-293. (PMID: 30068817)
      Am J Kidney Dis. 2009 Jun;53(6):982-92. (PMID: 19339088)
      Eur Heart J. 2019 Jul 03;:. (PMID: 31270529)
      Diabetes Obes Metab. 2005 Jan;7(1):83-7. (PMID: 15642079)
      J Lipid Res. 2010 Jan;51(1):140-9. (PMID: 19571328)
      Clin Chem. 2009 Sep;55(9):1637-45. (PMID: 19628659)
      Clin Chim Acta. 1994 Mar;225(2):105-13. (PMID: 8088000)
      Clin Genet. 2004 May;65(5):419-22. (PMID: 15099351)
      Lipids Health Dis. 2016 Sep 22;15(1):165. (PMID: 27658826)
      Cardiovasc Diabetol. 2016 Aug 04;15(1):107. (PMID: 27488210)
      Int J Med Sci. 2013;10(2):124-32. (PMID: 23329883)
      Circulation. 2016 Mar 29;133(13):1230-9. (PMID: 26896437)
      Clin Chem. 2012 Jan;58(1):183-9. (PMID: 22065156)
      Atherosclerosis. 2015 Apr;239(2):577-82. (PMID: 25734981)
      Clin Biochem. 2020 Mar;77:20-25. (PMID: 31972148)
      J Diabetes Complications. 2015 Nov-Dec;29(8):1165-70. (PMID: 26412029)
      J Biol Chem. 2006 Mar 10;281(10):6211-8. (PMID: 16407292)
      Diabetes Res Clin Pract. 2014 Oct;106(1):128-35. (PMID: 25110104)
      Am J Cardiol. 2016 Jul 15;118(2):198-203. (PMID: 27241838)
      Intern Med. 2007;46(16):1283-4. (PMID: 17704603)
      Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. (PMID: 28644091)
      Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1589-96. (PMID: 26023080)
      Biofactors. 2015 Sep-Oct;41(5):339-51. (PMID: 26354227)
      Heart Lung Circ. 2016 May;25(5):520-5. (PMID: 26706651)
      Hum Genet. 1991 Apr;86(6):607-14. (PMID: 2026424)
      Atheroscler Suppl. 2015 May;18:263-7. (PMID: 25936335)
      Am J Cardiol. 2004 Jun 15;93(12):1473-80. (PMID: 15194016)
      J Atheroscler Thromb. 2020 May 1;27(5):471-484. (PMID: 31748467)
      Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S337-S341. (PMID: 28283395)
      Atherosclerosis. 2019 Oct;289:201-205. (PMID: 31327478)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      Clin Biochem. 2014 Aug;47(12):1033-9. (PMID: 24721682)
    • Contributed Indexing:
      Keywords: Epidemiology; Insulin resistance; Lipoprotein(a); Proprotein convertase subtilisin/kexin type 9 (PCSK9)
    • Accession Number:
      0 (Cholesterol, LDL)
      0 (Lipoprotein(a))
      0 (Triglycerides)
      EC 3.4.21.- (PCSK9 protein, human)
      EC 3.4.21.- (Proprotein Convertase 9)
    • Publication Date:
      Date Created: 20200707 Date Completed: 20211112 Latest Revision: 20211112
    • Publication Date:
      20221213
    • Accession Number:
      PMC8147011
    • Accession Number:
      10.5551/jat.56390
    • Accession Number:
      32624555